Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1378874

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1378874

Osteoporosis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

PUBLISHED:
PAGES: 149 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2499
PDF & Excel (5 User License)
USD 3499
PDF & Excel (Corporate License)
USD 4499

Add to Cart

Abstract

The global osteoporosis drugs market size reached US$ 15.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 21.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.9% during 2022-2028.

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type and route of administration.

Breakup by Product Type:

Bisphosphonates

Calcitonin

Rank Ligand Inhibitor

Parathyroid Hormone Therapy (PTH)

Selective Estrogen Receptor Modulators (SERMs)

Sclerostin Inhibitor

Others

Breakup by Route of Administration:

Oral

Injectable

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report

  • 1. How big is the global osteoporosis drugs market?
  • 2. What is the expected growth rate of the global osteoporosis drugs market during 2023-2028?
  • 3. What are the key factors driving the global osteoporosis drugs market?
  • 4. What has been the impact of COVID-19 on the global osteoporosis drugs market?
  • 5. What is the breakup of the global osteoporosis drugs market based on the product type?
  • 6. What is the breakup of the global osteoporosis drugs market based on the route of administration?
  • 7. What are the key regions in the global osteoporosis drugs market?
  • 8. Who are the key players/companies in the global osteoporosis drugs market?
Product Code: SR112023A3104

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Osteoporosis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Bisphosphonates
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcitonin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rank Ligand Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Parathyroid Hormone Therapy (PTH)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Selective Estrogen Receptor Modulators (SERMs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Sclerostin Inhibitor
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Eli Lilly and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 F. Hoffmann-La Roche AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Merck & Co. Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Novartis AG
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Pfizer Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Radius Health Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Teva Pharmaceutical Industries Ltd.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 UCB S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
Product Code: SR112023A3104

List of Figures

  • Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2022
  • Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2022
  • Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2022
  • Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
  • Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
  • Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million US$), 2023-2028
  • Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
  • Table 6: Global: Osteoporosis Drugs Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!